A team of researchers from Taiwan found that patients with systemic lupus erythematosus (SLE) have higher levels of T helper 17 cells than healthy controls, thus encouraging research in IL-17/IL-17R blockades as a potential treatment targets for SLE. The study entitled “Increased Th17 cells in flow…
Researchers at Brigham and Women’s Hospital in Boston, Massachusetts, discovered that systemic lupus erythematosus (SLE) has lower mortality rates in Asian and Hispanic patients when compared to Black, White or Native American patients. The study entitled “Racial/Ethnic Variation in All-Cause Mortality among U.S. Medicaid Recipients…
Systemic lupus erythematosus (SLE) is an immune multi-systemic autoimmune condition that mainly affects young women. Current evidence from population-based studies and randomized controlled trials indicated the onset of SLE and lupus flares is triggered by various environmental factors, such as cigarette smoke, alcohol, occupationally- and non-occupationally-related chemicals, ultraviolet light,…
23andMe, Inc., a personal genetics company that helps people better understand and benefit from the human genome, recently announced a new partnership with Pfizer Inc. that will give them access to 23andMe’s research platform, which includes data of the genotypes from more than 800,000 individuals that consented to enroll in the study. From this partnership and…
A national leader in lupus research and chief of Rheumatology at the Beth Israel Deaconess Medical Center (BIDMC) George Tsokos, MD, was recently awarded with two prestigious awards by the Lupus Foundation of America and the American College of Rheumatology (ACR) during the 2014 ACR Annual Scientific Meeting held in Boston.
Christopher Sjöwall from the Rheumatology/AIR Department of Clinical and Experimental Medicine at Linköping in Sweden and colleagues, evaluated the performance of the Systemic Lupus International Collaborating Clinics (SLICC) criteria created in 2012 (SLIC-12) in a European population of patients with systemic lupus erythematosus (SLE). The study…
The Kadmon Corporation’s Phase 2 oral drug, KD025, a potent, bio-available and highly selective inhibitor of ROCK2 (Rho-associated coiled-coiled kinase 2) that can be taken orally was designed as one of its priority candidates to treat lupus through the LRxL-STAT Lupus Drug Repositioning Initiative. The selection of the drug was presented at the annual American College…
A new case study entitled “Acute kidney injury associated with minimal change disease in systemic lupus erythematosus: a case report” describes a rare case of a patient with Systemic lupus erythematosus and acute kidney injury associated with minimal change disease. The study was published in the Journal…
A clinical review entitled “Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: a review of literature” was recently published in the journal Pediatric Rheumatology. Juvenile-onset systemic lupus erythematosus (JSLE) is a common systemic autoimmune connective tissue condition that affects children. Estimations of JSLE are of…
Biopharmaceutical company Anthera Pharmaceuticals, Inc. is hosting a symposium on Systemic Lupus Erythematosus (SLE) designed for shareholders and investors, which is taking place on Wednesday, January 14, at 3:30 pm at the Mystic Hotel in San Francisco, CA. Anther is focused on the development and commercialization of medical options for the treatment of…